학술논문

Disparities in Lung Cancer Treatment
Document Type
Review Paper
Source
Current Oncology Reports. 24(2):241-248
Subject
Racial disparities
Non-small cell lung cancer
Guideline-concordant treatment
Molecular biomarker testing utilization
Social determinants of health
Next-generation sequencing
Clinical trials
Chemotherapy
Radiation and surgery
Black-White disparity
Language
English
ISSN
1523-3790
1534-6269
Abstract
Purpose of Review: Despite an overall reduction in lung cancer incidence and mortality rates worldwide, Blacks still have higher mortality rates compared to Whites. There are many factors that contribute to this difference. This review seeks to highlight racial disparities in treatment and the possible reasons for these disparities.Recent Findings: Factors attributing to racial disparities in lung cancer treatment include social determinants of health, differences in the administration of guideline-concordant therapy as well as molecular testing that is essential for most NSCLC patients.Summary: One way to circumvent disparities in lung cancer survivorship is to ensure equal representation of race in research at all levels that will provide insight on interventions that will address social determinants of health, differences in treatment patterns, molecular testing, and clinical trial involvement.